Calando Pharmaceuticals, Pasadena, California, USA.
Pharm Res. 2011 Feb;28(2):187-99. doi: 10.1007/s11095-010-0178-7. Epub 2010 Jun 12.
Nanoparticle approaches to drug delivery for cancer offer exciting and potentially "game-changing" ways to improve patient care and quality of life in numerous ways, such as reducing off-target toxicities by more selectively directing drug molecules to intracellular targets of cancer cells. Here, we focus on technologies being investigated clinically and discuss numerous types of therapeutic molecules that have been incorporated within nanostructured entities such as nanoparticles. The impacts of nanostructured therapeutics on efficacy and safety, including parameters like pharmacokinetics and biodistribution, are described for several drug molecules. Additionally, we discuss recent advances in the understanding of ligand-based targeting of nanoparticles, such as on receptor avidity and selectivity.
纳米颗粒药物递送方法为癌症治疗提供了令人兴奋且具有潜在“变革性”的途径,可以通过更有选择性地将药物分子靶向癌细胞的细胞内靶标,从而减少非靶标毒性,从而在许多方面改善患者的护理和生活质量。在这里,我们重点关注正在临床研究的技术,并讨论了许多已被纳入纳米结构实体(如纳米颗粒)中的治疗分子类型。对于几种药物分子,我们描述了纳米结构疗法对疗效和安全性的影响,包括药代动力学和生物分布等参数。此外,我们还讨论了对纳米颗粒基于配体靶向的理解方面的最新进展,例如对受体亲和力和选择性的理解。